We analyzed publicly available (TCGA) RNA-seq datasets and found that patients with high STAT5A mRNA expressing breast tumors had a significantly higher overall survival (p = 0.002) and progression-free interval (p = 0.047) compared to patients with tumors that have low STAT5A (Fig. 4f). The gene discussed is STAT5A; the disease is breast neoplasm.